317 related articles for article (PubMed ID: 26248473)
1. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
Zhang Y; Wang F; Ding J; Zhang H; Liu X; Wang S; Xiao H; Yao Y; Liu J; Zhong X; Guan N; Su B; Wu G; Yu L
Pediatr Nephrol; 2016 Jan; 31(1):67-72. PubMed ID: 26248473
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
3. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
Webb NJ; Shahinfar S; Wells TG; Massaad R; Gleim GW; McCrary Sisk C; Lam C
Pediatr Nephrol; 2013 May; 28(5):737-43. PubMed ID: 23207876
[TBL] [Abstract][Full Text] [Related]
4. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
5. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
6. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
[TBL] [Abstract][Full Text] [Related]
7. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
8. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
9. An update on the pathomechanisms and future therapies of Alport syndrome.
Noone D; Licht C
Pediatr Nephrol; 2013 Jul; 28(7):1025-36. PubMed ID: 22903660
[TBL] [Abstract][Full Text] [Related]
10. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?
Hilgers KF; Dötsch J; Rascher W; Mann JF
Pediatr Nephrol; 2004 Sep; 19(9):956-61. PubMed ID: 15278690
[TBL] [Abstract][Full Text] [Related]
12. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
Daina E; Cravedi P; Alpa M; Roccatello D; Gamba S; Perna A; Gaspari F; Remuzzi G; Ruggenenti P
Nephron; 2015; 130(1):13-20. PubMed ID: 25895746
[TBL] [Abstract][Full Text] [Related]
13. Losartan and enalapril are comparable in reducing proteinuria in children.
Webb NJ; Shahinfar S; Wells TG; Massaad R; Gleim GW; Santoro EP; Sisk CM; Lam C
Kidney Int; 2012 Oct; 82(7):819-26. PubMed ID: 22739977
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
Edström Halling S; Söderberg MP; Berg UB
Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.
Kaseda R; Tsuchida Y; Gamboa JL; Zhong J; Zhang L; Yang H; Dikalova A; Bian A; Davies S; Fogo AF; Linton MF; Brown NJ; Ikizler TA; Kon V
Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):582-591. PubMed ID: 29691148
[TBL] [Abstract][Full Text] [Related]
19. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease.
Manns B; Tonelli M; Culleton B; Faris P; McLaughlin K; Chin R; Gooch K; McAlister FA; Taub K; Thorlacius L; Krause R; Kearns M; Hemmelgarn B;
Clin J Am Soc Nephrol; 2012 Apr; 7(4):565-72. PubMed ID: 22344504
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure during lisinopril and losartan therapy for proteinuria.
Hanevold CD
Pharmacotherapy; 2006 Sep; 26(9):1348-51. PubMed ID: 16945058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
